The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

Vorinostat (SAHA) is a histone deacetylase inhibitor that exerts its effects through epigenetic regulation. Specifically, SAHA can inhibit the proliferation of triple-negative breast cancer (TNBC) cells alone or in combination with other chemotherapeutic agents. Doxorubicin (DOX), a traditional chem...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, Wenjing Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-10-01
coleção:	Pharmacological Research
Assuntos:	Triple negative breast cancer Cancer stem cells Tumor immune microenvironment Vorinostat Doxorubicin
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1043661823002827
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!